Monthly Archives: May 2011
Shrinks Like Latuda Over the Competition, Survey Finds
Psychiatrists are more likely to recommend Sunovion Pharmaceuticals’ Latuda to colleagues than Merck’s Saphris or Novartis’ Fenapt, according to a DTW Marketing Research survey.
All three drugs are atypical antipsychotics indicated for schizophrenia, and had US launches in late 2009 (Saphris), early 2010 (Fenapt) and February of this year (Latuda). Latuda, however, appears to be gaining [...]
Posted in Advertising, Marketing, Sales, Strategy, patient compliance Tagged brand, sales force 3 Comments
Will the iPad Replace the Rep?
By Beth Kennedy.
With Big Pharma sales teams awash with iPads and 72% of US doctors now armed with smartphones for professional use, are we finally approaching the day when the rep is replaced by digital technology? And if so, is it a good idea?
The number of pharma sales reps industry has fallen by more than [...]
Posted in Guest Blog, Marketing, Sales, Strategy, social media Tagged digital marketing, iPad, pharma sales, physicians, Sales, Sales Reps 2 Comments
Allergan Offers to Pay Journos to Discuss Botox
Physicians aren’t the only ones getting paid to attend industry-sponsored events heavy on product discussions. For $250, “select” journalists can discuss facial aesthetics at an event sponsored by Botox-maker Allergan, on June 9 in New York City. Journalistic ethics can be checked at the door.
The emailed invitation to attend Allergan’s Facial Aesthetics Advisory Panel, which [...]
Posted in Events, Strategy, Uncategorized Tagged Allergan, faux pas, healthcare, public relations 1 Comment
Gift Giving Must Stop Says ProPublica
According to ProPublica—though transparency has seemingly increased between pharma and physicians since the Christmastime release of its Dollars for Docs report—medical societies and organizations are still having a holiday with industry money.
Three days before Christmas last year, independent news organization ProPublica released its own “naughty and nice” list in the form of its Dollars for [...]

Biosimilars Spend to Reach $2.5 Bln by 2015: IMS